# 119-hr-4570: Interagency Patent Coordination and Improvement Act of 2025

119-hr-4570, Interagency Patent Coordination and Improvement Act of 2025, is a 119th Congress bill sponsored by Rep. Neguse, Joe [D-CO-2] (D-CO); status introduced (as of 2026-04-21).

- Canonical: https://policyrisk.com/legislation/119-hr-4570
- As of: 2026-04-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-4570
- Congress: 119
- Title: Interagency Patent Coordination and Improvement Act of 2025
- Status: introduced
- Introduced: 2025-07-21
- Sponsor: Rep. Neguse, Joe [D-CO-2] (D-CO)
- Cosponsors: 0
- Policy area: Commerce
- Touches household money: no
- Last recorded action: 2026-04-21

## Summary

**Creates an interagency task force to let the USPTO and FDA share technical and regulatory information about human drugs and biological products to improve patent examination.** It would set rules for sharing FDA approvals, labeling updates, indications, and certain nonpublic communications while protecting confidentiality and preserving each agency's ministerial roles. - Patent examiners and patent applicants would gain access to FDA-provided data and certain nonpublic FDA communications on approvals, label changes, and indications to better assess prior art and on-sale issues. - Drug sponsors and manufacturers would get at least 30 days' notice before the FDA shares confidential information and the bill requires safeguards, separation from pending patent applications, and remedies for unauthorized disclosure. - The USPTO Director and FDA Commissioner would coordinate the task force via a memorandum of understanding and must report to the House and Senate Judiciary Committees within 4 years on how information sharing worked and what changes are recommended.

## Provisions PRIA read

- New drug patent task force: benefit, low. If enacted, the government would set up a joint task force for drug and biologic patents. The USPTO Director and FDA Commissioner would run it and pick members. They would sign or update a memorandum of understanding to guide how it works. When making patent decisions on drugs or biologics, the USP…
- Patent info sharing with safeguards: benefit, low. If enacted, the task force would hold regular meetings and training to share how the USPTO and FDA review cases. The USPTO Director could ask the FDA for specific information to help examiners, only as needed for patent work. Confidential records could be shared with safeguards. Drug or biologic sp…

## Related bills

- 119-hr-3151: SHIPS for America Act of 2025
- 119-hr-7977: Energy Bills Relief Act
- 119-hr-10061: Wildfire Response and Readiness Act
- 119-hr-7973: Momnibus Act
- 119-hr-9070: OPEN Act
- 119-hr-5782: Western Wildfire Support Act of 2025

## Sources
- [119-hr-4570 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/4570)

## Related
- [119-hr-3151: SHIPS for America Act of 2025](https://policyrisk.com/legislation/119-hr-3151)
- [119-hr-7977: Energy Bills Relief Act](https://policyrisk.com/legislation/119-hr-7977)
- [119-hr-10061: Wildfire Response and Readiness Act](https://policyrisk.com/legislation/119-hr-10061)
- [119-hr-7973: Momnibus Act](https://policyrisk.com/legislation/119-hr-7973)
- [119-hr-9070: OPEN Act](https://policyrisk.com/legislation/119-hr-9070)
- [119-hr-5782: Western Wildfire Support Act of 2025](https://policyrisk.com/legislation/119-hr-5782)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-4570 (as of 2026-04-21).